Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureColm Bradley, Argiris Symeonidis, Nkemdirim Jacob
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Gaucher disease—more than just a rare lipid storage disease
10.1007/s00109-021-02174-z · 2022
Hematological manifestations and complications of Gaucher disease
10.1080/17474086.2021.1908120 · 2021
Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians
10.1016/j.ymgme.2017.08.002 · 2017
Glycosphingolipids and lysosomal storage disorders as illustrated by Gaucher disease
10.1016/j.cbpa.2019.10.006 · 2019
Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis
10.1182/blood-2011-10-386862 · 2012
Gaucher disease epidemiology and natural history: a comprehensive review of the literature
10.1080/10245332.2016.1240391 · 2017
Hemostatic abnormalities in Gaucher disease: mechanisms and clinical implications
10.3390/jcm11236920 · 2022
The definition of neuronopathic Gaucher disease
10.1002/jimd.12235 · 2020
Glucosylsphingosine (Lyso‐Gb1) as a reliable biomarker in Gaucher disease: a narrative review
10.1186/s13023-023-02623-7 · 2023
Scoring system to facilitate diagnosis of Gaucher disease
10.1111/imj.14942 · 2020
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease
10.1016/j.bcmd.2016.10.008 · 2018
Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment
10.1016/j.ymgme.2020.12.295 · 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
10.1002/ajh.26276 · 2021
Small molecule chaperones for the treatment of Gaucher disease and GBA1‐associated Parkinson disease
10.3389/fcell.2020.00271 · 2020
Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
10.1002/ajh.26675 · 2022
No additional external references are available.